The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP). This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
FibroBiologics, Inc. has announced the completion of its proprietary master cell bank, which will support its upcoming clinical trials. Developed in partnership with Charles River Laboratories and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results